My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Obatoclax Mesylate (GX15-070)
    Obatoclax Mesylate (GX15-070)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0004
    CAS #: 803712-79-0Purity ≥98%

    Description: Obatoclax Mesylate (also known as GX15 070), the mesylate salt of obatoclax, is a potent inhibitor of Bcl-2 (B-cell leukemia protein-2) protein with a Ki of 0.22 μM in a cell-free assay. Obatoclax binds to the BH3-binding site of BCL-2 and other related BCL-2 family members (including BCL-XL, MCL-1, A1, and BCL-B).  As a pan-BCL-2 inhibitor, it is being investigated for the treatment of refractory malignancies, obatoclax mesylate directly induce apoptosis in cultured acute myeloid leukemia (AML) cells as well as primary patient samples and exhibits antitumor activity in mouse xengografts of solid tumor and myeloma cell lines. The Bcl-2 family of proteins are overexpressed in various cancers such as the lymphatic system, breast, lung, prostate, and colon. Therefore, Obatoclax has anticancer activity as an Bcl-2 inhibitor.

    References: Proc Natl Acad Sci, 2007, 104(49), 19512-191517.

    Customer Validation
    Top Publications Citing Invivochem Products
    • Citation of InvivoChem Vorinostat (V0255) by Nature 2021, 597(7874):119-125
    • Citation of InvivoChem Larotrectinib (V2599) by Cell. 2020 Nov 25;183(5):1202-1218.e25
    • Citation of InvivoChem Eprenetapopt (APR-246) by Science Adv 2022: 8, eabm9427.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3
    • Citation of InvivoChem Larotrectinib (V2599) by Cell 2020, doi: 10.1016/j.cell.2020.10.016.
    • Citation of InvivoChem Eprenetapopt (APR-246) by Science Adv 2022, doi: 10.1126/sciadv.abm9427.
    • Citation of InvivoChem Vorinostat/SAHA (V0255) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem Vitrakvi by Cell 2020, PMID: 33142117 PMCID: PMC8100789
    • Citation of InvivoChem APR-246 by Science Adv 2022, PMID: 36103522.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem LOXO-101 by Cell 2020, PMID: 33142117 PMCID: PMC8100789
    • Citation of InvivoChem Eprenetapopt by Science Adv 2022, PMID: 36103522.
    • Citation of InvivoChem Vorinostat/SAHA (V0255) by Nature 2021, PMID: 34433969
    • Citation of InvivoChem  ARRY-470 by Cell 2020, PMID: 33142117 PMCID: PMC8100789
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, PMID: 34433969
    • Citation of InvivoChem BMH-21 (V1435) by Cell Stem Cell 2020, 26(6): 845-861.e12.
    • Citation of InvivoChem Eprenetapopt (APR-246) by Science Adv 2022, doi: 10.1126/sciadv.abm9427.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem V33339 Lys-SMCC-DM1 by PNAS Nexus 2022, pgac063, https://academic.oup.com/pna
    • Citation of InvivoChem 5-azacytidine by Nature 2021, PMID: 34433969
    • Citation of InvivoChem Ruxolitinib/Filgotinib/BMS-911543/Decernotinib by J Allergy Clin Immunol 2020
    • Citation of InvivoChem LGK974 /WNT974 (V1353) by  Cancer Cell 2021 Apr 12;39(4):529-547.e7.
    • Citation of InvivoChem V1386 Napabucasin (BBI-608) by J Exp Clin Cancer Res 2021 Oct 13;40(1):319.
    • Citation of InvivoChem 5-azacytidine (V0404) by Nature 2021, DOI: 10.1038/s41586-021-03850-3.
    • Citation of InvivoChem Epacadostat/INCB024360 (V0942) by Cancer Discov 2022: 12(4):1106-1127.
    • Citation of InvivoChem S63845 (V2797) by Cell Death and Disease 2020, 11:316.
    • Citation of InvivoChem BMS-582949 (V2668) by Cells 2020, 9(6):1472.
    • Citation of InvivoChem Apiin (V4467) by J Med Chem 2020, 63(15):8338-8358.
    • Citation of InvivoChem V0001 venetoclax by WO2021231323A1
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)413.49
    FormulaC20H19N3O.CH4O3S
    CAS No.803712-79-0
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 83 mg/mL (200.7 mM)
    Water:<1 mg/mL (slightly soluble or insoluble)
    Ethanol:<1 mg/mL
    Solubility (In vivo)30% PEG400+0.5% Tween80+5% Propylene glycol: 30 mg/mL
    SynonymsGX015070; GX-015070; GX 05-070; GX 015-070; GX015-070; GX-015-070; GX 015070; GX15070MS.


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    GeneralObatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. 
    Animal modelFemale BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells.
    FormulationObatoclax (tartrate salt) is formulated in 9.6% PEG300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated  in 9.48% PEG, 0.38% polysorbate 20.
    Dosages0.0313, 0.25, 0.5 and 2 mg/kg
    AdministrationIntravenously (tail vein) once a day
    ReferencesNguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    Obatoclax Mesylate (GX15-070)Obatoclax induces massive necrosis in mouse and human thyroid cancer cells.  2016 Jun 7;7(23):34453-71.Obatoclax Mesylate (GX15-070)Obatoclax blocks late authophagy, unrelated to cell death.  2016 Jun 7;7(23):34453-71.Obatoclax Mesylate (GX15-070) Obatoclax autofluorescence reveals its accumulation in lysosomes.  2016 Jun 7;7(23):34453-71.
    Obatoclax Mesylate (GX15-070)Obatoclax induces morphological and functional alterations in lysosomes.  2016 Jun 7;7(23):34453-71.Obatoclax Mesylate (GX15-070)Lysosomal acidic environment is critical for necrotic death induced by Obatoclax.  2016 Jun 7;7(23):34453-71.Obatoclax Mesylate (GX15-070) Mouse and human thyroid cancer cells are sensitive to lysosomal destabilization.  2016 Jun 7;7(23):34453-71.
    Obatoclax Mesylate (GX15-070) Obatoclax does not induce massive LMP, and its effect is independent of BCL2 proteins.  2016 Jun 7;7(23):34453-71.Obatoclax Mesylate (GX15-070)
    Obatoclax Mesylate (GX15-070)
     Obatoclax Mesylate (GX15-070)


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?